• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Dupuytren 病的科学认识和临床管理。

Scientific understanding and clinical management of Dupuytren disease.

机构信息

Plastic & Reconstructive Surgery Research, School of Translational Medicine, Manchester Academic Health Science Centre, Manchester Interdisciplinary Biocentre, University of Manchester, 131 Princess Street, Manchester M1 7ND, UK.

出版信息

Nat Rev Rheumatol. 2010 Dec;6(12):715-26. doi: 10.1038/nrrheum.2010.180. Epub 2010 Nov 9.

DOI:10.1038/nrrheum.2010.180
PMID:21060335
Abstract

Dupuytren disease (DD) is a fibroproliferative disorder of unknown etiology that often results in shortening and thickening of the palmar fascia, leading to permanent and irreversible flexion contracture of the digits. This Review provides a detailed update of the scientific understanding of DD and its clinical management, with perspectives on emerging research and therapy. Established risk factors include genetic predisposition and ethnicity, as well as sex and age. Several environmental risk factors (some considered controversial) include smoking, alcohol intake, trauma, diabetes, epilepsy and use of anticonvulsant drugs, and exposure to vibration. DD has been variously attributed to the presence of oxygen free radicals, trauma to the palmar fascia, or aberrant immune responses with altered antigen presentation, or to interactions between these proposed mechanisms. The presence of immune cells and related phenomena in DD-affected tissue suggests that DD is possibly immune-related. Mechanically, digital contracture is caused by myofibroblasts in the DD palmar fascia; however, the exact origin of this cell type remains unknown. The mainstay of treatment is surgical release or excision of the affected palmodigital tissue, but symptoms often recur. Nonsurgical correction of DD contractures can be achieved by Clostridium histolyticum collagenase injection, although the long-term safety and recurrence rate of this procedure requires further assessment.

摘要

掌腱膜挛缩症(Dupuytren 病,DD)是一种病因不明的纤维增生性疾病,常导致掌筋膜缩短和增厚,导致手指永久性和不可逆的弯曲挛缩。本综述详细介绍了对 DD 的科学认识及其临床管理的最新进展,包括对新兴研究和治疗方法的展望。已确定的风险因素包括遗传易感性和种族,以及性别和年龄。一些环境风险因素(有些被认为有争议)包括吸烟、饮酒、创伤、糖尿病、癫痫和使用抗癫痫药物,以及接触振动。DD 归因于氧自由基的存在、掌筋膜的创伤,或异常的免疫反应导致抗原呈递改变,或这些拟议机制之间的相互作用。DD 受累组织中免疫细胞和相关现象的存在表明 DD 可能与免疫有关。在机械方面,手指挛缩是由 DD 掌筋膜中的肌成纤维细胞引起的;然而,这种细胞类型的确切来源仍不清楚。该病的主要治疗方法是手术松解或切除受累的掌指组织,但症状常复发。通过注射胶原酶(如注射型 A 型肉毒毒素)可以非手术矫正 DD 挛缩,但该方法的长期安全性和复发率仍需进一步评估。

相似文献

1
Scientific understanding and clinical management of Dupuytren disease.Dupuytren 病的科学认识和临床管理。
Nat Rev Rheumatol. 2010 Dec;6(12):715-26. doi: 10.1038/nrrheum.2010.180. Epub 2010 Nov 9.
2
Minimally Invasive Treatments of Dupuytren Disease: An Overview.《掌腱膜挛缩症的微创治疗:概述》。
J Hand Surg Asian Pac Vol. 2021 Jun;26(2):131-141. doi: 10.1142/S2424835521400026.
3
Risk Factors, Disease Associations, and Dupuytren Diathesis.风险因素、疾病关联与掌腱膜挛缩素质
Hand Clin. 2018 Aug;34(3):307-314. doi: 10.1016/j.hcl.2018.03.002.
4
Dupuytren Contractures: An Update of Recent Literature.掌腱膜挛缩症:最新文献综述。
J Hand Surg Am. 2021 Oct;46(10):896-906. doi: 10.1016/j.jhsa.2021.07.005. Epub 2021 Aug 25.
5
Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data.溶组织梭状芽孢杆菌胶原酶治疗后掌腱膜挛缩复发情况(CORDLESS [胶原酶用于掌腱膜挛缩减少的长期安全性评估研究]):5年数据
J Hand Surg Am. 2015 Aug;40(8):1597-605. doi: 10.1016/j.jhsa.2015.04.036. Epub 2015 Jun 18.
6
The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease.胶原酶在治疗杜普伊特伦挛缩症中的新兴作用。
Ther Clin Risk Manag. 2010 Nov 4;6:557-72. doi: 10.2147/TCRM.S8591.
7
[Dupuytren's disease treatment].[杜普伊特伦挛缩症的治疗]
Ugeskr Laeger. 2015 Mar 9;177(11).
8
Dupuytren disease: an evolving understanding of an age-old disease.杜普伊特伦挛缩症:一种古老疾病的不断演变的认识。
J Am Acad Orthop Surg. 2011 Dec;19(12):746-57. doi: 10.5435/00124635-201112000-00005.
9
Outcome of Dupuytren Contractures After Collagenase Clostridium Histolyticum Injection: A Single-institution Experience.注射溶组织梭状芽孢杆菌胶原酶后掌腱膜挛缩症的治疗结果:单机构经验
Ann Plast Surg. 2017 Aug;79(2):145-148. doi: 10.1097/SAP.0000000000001068.
10
DupuytrEn Treatment EffeCtiveness Trial (DETECT): a protocol for prospective, randomised, controlled, outcome assessor-blinded, three-armed parallel 1:1:1, multicentre trial comparing the effectiveness and cost of collagenase clostridium histolyticum, percutaneous needle fasciotomy and limited fasciectomy as short-term and long-term treatment strategies in Dupuytren's contracture.杜普伊特伦挛缩治疗效果试验(DETECT):一项前瞻性、随机、对照、结果评估者盲法、三臂平行1:1:1多中心试验方案,比较溶组织梭状芽孢杆菌胶原酶、经皮针状筋膜切开术和有限筋膜切除术作为杜普伊特伦挛缩短期和长期治疗策略的有效性和成本。
BMJ Open. 2018 Mar 28;8(3):e019054. doi: 10.1136/bmjopen-2017-019054.

引用本文的文献

1
Associations of Demographic, Lifestyle, and Clinical Factors With the Presence of Dupuytren Disease: Results from the Lifelines Cohort Study.人口统计学、生活方式和临床因素与掌腱膜挛缩症的相关性:生命线队列研究结果
J Hand Surg Glob Online. 2025 Jul 24;7(5):100786. doi: 10.1016/j.jhsg.2025.100786. eCollection 2025 Sep.
2
Angiotensin Receptor Autoantibodies in Dupuytren Disease: A Biomarker Study.掌腱膜挛缩症中的血管紧张素受体自身抗体:一项生物标志物研究。
Plast Surg (Oakv). 2025 Jun 5:22925503251344305. doi: 10.1177/22925503251344305.
3
Outcomes of limited fasciectomy, needle fasciotomy and collagenase injection for Dupuytren's disease: a systematic review and meta-analysis of individual patient data.

本文引用的文献

1
Unique microRNA profile in Dupuytren's contracture supports deregulation of β-catenin pathway.独特的 miRNA 图谱在杜普伊特伦挛缩中支持β-连环蛋白途径的失调。
Mod Pathol. 2010 Nov;23(11):1544-52. doi: 10.1038/modpathol.2010.146. Epub 2010 Jul 30.
2
Genome-wide high-resolution screening in Dupuytren's disease reveals common regions of DNA copy number alterations.掌腱膜挛缩症的全基因组高分辨率筛查揭示了DNA拷贝数改变的常见区域。
J Hand Surg Am. 2010 Jul;35(7):1172-1183.e7. doi: 10.1016/j.jhsa.2010.03.006. Epub 2010 Jun 19.
3
Collagenase injection as nonsurgical treatment of Dupuytren's disease: 8-year follow-up.
掌腱膜挛缩症的有限筋膜切除术、经皮筋膜切开术和胶原酶注射治疗结果:个体患者数据的系统评价和荟萃分析
J Hand Surg Eur Vol. 2025 Jul;50(7):878-890. doi: 10.1177/17531934251338349. Epub 2025 May 20.
4
Management of Dupuytren's Disease: A Multi-Centric Comparative Analysis Between Experienced Hand Surgeons Versus Artificial Intelligence.掌腱膜挛缩症的治疗:经验丰富的手外科医生与人工智能之间的多中心比较分析
Diagnostics (Basel). 2025 Feb 28;15(5):587. doi: 10.3390/diagnostics15050587.
5
Public Awareness of Dupuytren's Contracture in Saudi Arabia.沙特阿拉伯公众对掌腱膜挛缩症的认知
Cureus. 2025 Feb 7;17(2):e78695. doi: 10.7759/cureus.78695. eCollection 2025 Feb.
6
RNA-seq unravels distinct expression profiles of keloids and Dupuytren's disease.RNA测序揭示了瘢痕疙瘩和掌腱膜挛缩症不同的表达谱。
Heliyon. 2023 Dec 13;10(1):e23681. doi: 10.1016/j.heliyon.2023.e23681. eCollection 2024 Jan 15.
7
C-X-C domain ligand 14-mediated stromal cell-macrophage interaction as a therapeutic target for hand dermal fibrosis.C-X-C 结构域配体 14 介导的基质细胞-巨噬细胞相互作用作为手部皮肤纤维化的治疗靶点。
Commun Biol. 2023 Nov 18;6(1):1173. doi: 10.1038/s42003-023-05558-8.
8
Let's Focus on the Fibrosis in Dupuytren Disease: Cell Communication Network Factor 2 as a Novel Target.让我们聚焦于掌腱膜挛缩症中的纤维化:细胞通讯网络因子2作为一个新靶点。
J Hand Surg Glob Online. 2023 Aug 1;5(5):682-688. doi: 10.1016/j.jhsg.2023.06.017. eCollection 2023 Sep.
9
Dupuytren contracture after acute traumatic hand injury in an adolescent: A case report.青少年急性创伤性手部损伤后的掌腱膜挛缩:病例报告。
Jt Dis Relat Surg. 2023 Aug 21;34(3):737-740. doi: 10.52312/jdrs.2023.1168.
10
A novel computationally engineered collagenase reduces the force required for tooth extraction in an ex-situ porcine jaw model.一种新型的通过计算设计的胶原酶在离体猪颌骨模型中降低了拔牙所需的力量。
J Biol Eng. 2023 Jul 17;17(1):47. doi: 10.1186/s13036-023-00366-4.
胶原酶注射作为杜普伊特伦挛缩症的非手术治疗:8年随访
J Hand Surg Am. 2010 Apr;35(4):534-9, 539.e1. doi: 10.1016/j.jhsa.2010.01.003.
4
Re-visiting Luck's classification: a histological analysis of Dupuytren's disease.重新审视勒克分类法:掌腱膜挛缩症的组织学分析
J Hand Surg Eur Vol. 2010 May;35(4):312-7. doi: 10.1177/1753193410362848. Epub 2010 Feb 24.
5
Radiotherapy in early-stage Dupuytren's contracture. Long-term results after 13 years.早期杜普伊特伦挛缩的放射治疗。13 年后的长期结果。
Strahlenther Onkol. 2010 Feb;186(2):82-90. doi: 10.1007/s00066-010-2063-z. Epub 2010 Jan 28.
6
Injectable collagenase clostridium histolyticum for Dupuytren's contracture.注射用溶组织梭菌胶原酶治疗掌腱膜挛缩症
N Engl J Med. 2009 Sep 3;361(10):968-79. doi: 10.1056/NEJMoa0810866.
7
Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells.骨膜蛋白可差异诱导原发性掌腱膜挛缩症及相邻掌侧筋膜细胞的增殖、收缩和凋亡。
Exp Cell Res. 2009 Dec 10;315(20):3574-86. doi: 10.1016/j.yexcr.2009.07.015. Epub 2009 Jul 18.
8
Type-1 Collagen differentially alters beta-catenin accumulation in primary Dupuytren's Disease cord and adjacent palmar fascia cells.I型胶原蛋白差异性地改变原发性掌腱膜挛缩症条索及相邻掌腱膜细胞中β-连环蛋白的积累。
BMC Musculoskelet Disord. 2009 Jun 19;10:72. doi: 10.1186/1471-2474-10-72.
9
Differential gene expression analysis of subcutaneous fat, fascia, and skin overlying a Dupuytren's disease nodule in comparison to control tissue.与对照组织相比,对Dupuytren病结节上方的皮下脂肪、筋膜和皮肤进行差异基因表达分析。
Hand (N Y). 2009 Sep;4(3):294-301. doi: 10.1007/s11552-009-9164-0. Epub 2009 Jan 29.
10
Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology.与病因相关的掌腱膜挛缩症发病率和患病率的流行病学评估。
Hand (N Y). 2009 Sep;4(3):256-69. doi: 10.1007/s11552-008-9160-9. Epub 2009 Jan 15.